Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted
Jia Jenny Liu/LinkedIn

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted

Jia (Jenny) Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, Conjoint Associate Professor at UNSW, shared on X:

“The ivonescimab FDA decision raises important questions beyond PFS vs OS.

As an Australian early-phase investigator, I increasingly see Chinese-origin oncology trials initiate enrolment domestically before expanding internationally.

This is not inherently problematic. But HARMONi highlights a challenge: staggered regional enrolment esp for P3 trials can create substantial differences in follow-up maturity, complicating interpretation of survival outcomes and regional consistency.

Global development requires more than international trial sites. It requires regulatory strategy, endpoint selection and regional enrolment planning from the outset.

The broader lesson? Global registrational readiness must be designed in, not retrofitted.

Source: Summit Therapeutics, HARMONi updated OS analysis, WCLC 2026 (15 September 2026).

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted

The ivonescimab FDA letter raises important questions extending beyond PFS versus OS.

Despite approximately 40% of patients being enrolled outside China, 93% of PFS events occurred in Chinese patients.

Geographic representation in trial enrolment does not necessarily translate into geographic representation in the events driving the primary endpoint.

Regional differences in enrolment timing and follow-up maturity may partly explain this imbalance, but the implications for international generalisability remain important.

The lesson? Design for global regulatory approval from the outset.

For emerging oncology drug developers: come and talk to us in Australia starting in Phase I!

We can help build globally relevant evidence from the earliest stages of clinical development.”

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted

You can also read: FDA Withholds Ivonescimab Approval in EGFR-Mutant NSCLC: Why HARMONi’s PFS Benefit Was Not Enough

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted